Publications by authors named "David A Fraser"

Claim this Profile
A
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
Stephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, Madhavi Rudraraju, Dean Tai, David A Fraser

J Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model.
Sarah Z Wang, Thomas I Hirsch, Scott C Fligor, Savas T Tsikis, Amy Pan, David A Fraser

Sci Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.
Bennet S Cho, Scott C Fligor, Gillian L Fell, Jordan D Secor, Savas T Tsikis, David A Fraser

PLoS One· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Medium-Chain Fatty Acid Analogue Prevents Intestinal Failure-Associated Liver Disease in Preterm Yorkshire Piglets.
Scott C Fligor, Savas T Tsikis, Thomas I Hirsch, Amy Pan, Kamila Moskowitzova, David A Fraser

Gastroenterology· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.
David A Fraser, Stephen A Harrison, Detlef Schuppan

Expert Opin Investig Drugs· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.
Jordon D Secor, Bennet S Cho, Lumeng J Yu, Amy Pan, Victoria H Ko, David A Fraser

Lipids· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
David A Fraser, Xiaoyu Wang, Jenny Lund, Nataša Nikolić, Marta Iruarrizaga-Lejarreta

J Hepatol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.
Geurt Stokman, Anita M van den Hoek, Ditte Denker Thorbekk, Elsbet J Pieterman, Sanne Skovgård Veidal, David A Fraser

Liver Int· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building capacity for injury prevention: a process evaluation of a replication of the Cardiff Violence Prevention Programme in the Southeastern USA.
Laura M Mercer Kollar, Steven A Sumner, Brad Bartholow, Daniel T Wu, Jasmine C Moore, David A Fraser

Inj Prev· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice.
Anita M van den Hoek, Elsbet J Pieterman, José W van der Hoorn, Marta Iruarrizaga-Lejarreta, Cristina Alonso, David A Fraser

Hepatol Commun· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ability of crime, demographic and business data to forecast areas of increased violence.
Daniel A Bowen, Laura M Mercer Kollar, Daniel T Wu, David A Fraser, Charles E Flood

Int J Inj Contr Saf Promot· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
John J P Kastelein, Jonas Hallén, Runar Vige, David A Fraser, Rong Zhou

Cardiology· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial.
David A Fraser, Lien M Diep, Inger Anette Hovden, Kristian B Nilsen, Kari Anne Sveen

Diabetes Care· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaborative science, policy development and program implementation in the transboundary Georgia Basin/Puget Sound ecosystem.
David A Fraser, Joseph K Gaydos, Erik Karlsen, Michael S Rylko

Environ Monit Assess· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphisms in an interferon-gamma receptor-1 gene marker and susceptibility to periodontitis.
David A Fraser, Bruno G Loos, Ulf Boman, Arie Jan van Winkelhoff, Ubele van der Velden

Acta Odontol Scand· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis